Endonovo Targets Dept. of Defense, VA & Federal Contracts
January 03, 2023 09:09 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) announced the advancement of its aggressive “Go to Market” strategy for expansion of SofPulse® medical...
Endonovo Launches Telehealth Initiative
December 13, 2022 09:11 ET
|
Endonovo Therapeutics, Inc.
Expands Patient Education, Access to Non-Opioid Options for Pain Management Los Angeles, CA, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced the...
Endonovo Therapeutics Issues Corporate Update
November 07, 2022 09:07 ET
|
Endonovo Therapeutics, Inc.
Highlights its previously-announced “Build Up Strategy” of acquiring complementary specialty service providers in the construction industry Los Angeles, CA, Nov. 07, 2022 (GLOBE NEWSWIRE) --...
Endonovo Therapeutics Signs Agreement with NAMSA to Develop Reimbursement Strategy for Endonovo Medical Products
April 25, 2022 09:08 ET
|
Endonovo Therapeutics, Inc.
LOS ANGELES, CA, April 25, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB:ENDV) today announced an agreement with NAMSA – a leading Global Contract Research Organization (CRO) and...
$5 Million Common Stock Offering for Endonovo Therapeutics Designed to Advance SofPulse® Process for Medical Reimbursement
April 11, 2022 09:08 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, April 11, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced significant advancement in the of process to obtain medical reimbursements for its...
Endonovo Therapeutics Issues Shareholder Update
October 12, 2021 16:05 ET
|
Endonovo Therapeutics, Inc.
High-Growth Acquisition Approaches Completion, Expected To Augment Core Business And Drive Long-Term Shareholder Value Los Angeles, CA, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc....
Stanford University Orthopedic Study Collaboration with Endonovo Therapeutics SofPulse® Devices Moves Forward
May 11, 2021 08:00 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, May 11, 2021 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced completion of Shipment of SofPulse® tPEMF Devices for use in...
Endonovo Therapeutics, Inc. Announces Second Quarter Fiscal 2020 Financial Results
August 20, 2020 14:51 ET
|
Endonovo Therapeutics, Inc.
LOS ANGELES, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced financial and operating results for the second quarter ended...
Endonovo Therapeutics Announces International Expansion with Distribution Agreement for SofPulse® in Taiwan, Republic of China
June 01, 2020 10:00 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, June 01, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced the signing of a Sales and Strategic Partnership Agreement...
Endonovo Therapeutics Announces Positive 2019 Fiscal Results
May 04, 2020 08:15 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, May 04, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today reported financial results for fiscal year ended December 31, 2019. ...